A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Inclusion Criteria:

• Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1or FGFR2 amplification or FGFR3 mutation, for which no further effective standardanticancer treatment exists

• Adequate bone marrow function

• Adequate hepatic and renal function

• Adequate cardiovascular function

• Contraception.

• For women: Must be surgically sterile, post-menopausal, or compliant with amedically approved contraceptive regimen during and for 3 months after thetreatment period; must have a negative serum or urine pregnancy test and must notbe nursing.

• For men: Must be surgically sterile or compliant with a contraceptive regimenduring and for 3 months after the treatment period

Exclusion Criteria:

• Patients with primary CNS tumor or CNS tumor involvement

• Patients with history and/or current evidence of endocrine alteration ofcalcium-phosphate homeostasis

• History and/or current evidence of ectopic mineralization/ calcification including butnot limited to the soft tissue, kidneys, intestine, myocard and lung with theexception of calcified lymphnodes and asymptomatic coronary calcification

• Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitisetc., confirmed by ophthalmologic examination.

• History or current evidence of cardiac arrhythmia and/or conduction abnormality

• Women who are pregnant or nursing. Other protocol-defined inclusion/exclusion criteria may apply